Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
A Prospective, Open-label, Dose Escalation,(Phase 1); Prospective, Randomized, Evaluator Blinded, Active-controlled, 2-sequence, 2-period, 2-treatment, Crossover(Phase 2); Phase 1/2 Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, Safety and Efficacy of GX-30 Administered Intramuscularly in Patients Underwent Total Thyroidectomy or Near Total Thyroidectomy
Sponsor: Genexine, Inc.
A PHASE1/PHASE2 clinical study on Near-total Thyroidectomy and Total Thyroidectomy, this trial is completed. The trial is conducted by Genexine, Inc. and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Dec 2018 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genexine, Inc.
- Symyoo
For direct contact, visit the study record on ClinicalTrials.gov .